The claims belong in federal court because the plaintiffs allege the companies violated the federal Food Drug and Cosmetic Act, were non-compliant with Food and Drug Administration guidance and that their refusal to submit the prescription pet food to FDA for review was improper, the U.S. Court of Appeals for the Eighth Circuit ruled Friday.
The ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.